

REVIEW

Circadian Rhythm, Clock Genes, and Hypertension: Recent Advances in Hypertension

Hannah M. Costello, Michelle L. Gumz 

ABSTRACT: Accumulating evidence suggests that the molecular circadian clock is crucial in blood pressure (BP) control. Circadian rhythms are controlled by the central clock, which resides in the suprachiasmatic nucleus of the hypothalamus and peripheral clocks throughout the body. Both light and food cues entrain these clocks but whether these cues are important for the circadian rhythm of BP is a growing area of interest. The peripheral clocks in the smooth muscle, perivascular adipose tissue, liver, adrenal gland, and kidney have been recently implicated in the regulation of BP rhythm. Dysregulation of the circadian rhythm of BP is associated with adverse cardiorenal outcomes and increased risk of cardiovascular mortality. In this review, we summarize the most recent advances in peripheral clocks as BP regulators, highlight the adverse outcomes of disrupted circadian BP rhythm in hypertension, and provide insight into potential future work in areas exploring the circadian clock in BP control and chronotherapy. A better understanding of peripheral clock function in regulating the circadian rhythm of BP will help pave the way for targeted therapeutics in the treatment of circadian BP dysregulation and hypertension.

Key Words: blood pressure ■ circadian rhythm ■ kidney diseases ■ suprachiasmatic nucleus ■ therapeutics

Hypertension is the leading modifiable risk factor for all-cause mortality, with the global burden estimated at 1.4 billion, $\approx 31\%$ of the global adult population.^{1–3} Diagnosis mainly relies on in-office or clinic blood pressure (BP) measurements, which do not account for variations in the circadian rhythm of BP.¹ Circadian rhythms are 24-hour oscillations that are imperative coordinators to many physiological functions, including BP regulation (reviewed in Douma and Gumz⁴). The daily BP rhythm is characterized by a morning surge on waking with a plateau during the day and a nocturnal decline (a decrease of 10%–20% from the average daytime BP). Ambulatory BP monitoring is essential for accounting for this 24-hour BP variation.^{1,5,6} Disruption of this 24-hour BP variation is more likely in patients with hypertension and chronic kidney disease (CKD) and is associated with adverse cardiorenal outcomes.^{7,8} Abnormal BP rhythms include nondipping BP (defined as a $<10\%$ decrease from daytime to nocturnal BP), reverse dipping (nocturnal risers), and extreme dippers ($\geq 20\%$ between nocturnal and daytime BP). Isolated nocturnal hypertension, defined as nighttime systolic BP ≥ 120 mm Hg and

diastolic BP ≥ 70 mm Hg with daytime $<135/85$ mm Hg,⁹ is usually associated with nondipping or reverse dipping but can be found in dippers.¹ Nocturnal hypertension and a nondipping pattern have been shown to increase the risk of hypertension-induced organ damage,¹⁰ with the worst outcomes seen in individuals who have both features.¹¹

Circadian rhythms are controlled by both the central clock, which resides in the suprachiasmatic nucleus (SCN) of the hypothalamus, and peripheral clocks throughout the body. The contribution of peripheral clocks, particularly the kidney clock, to BP rhythm is an active area of research (discussed in detail below). At the molecular level, this is controlled by a cellular clock, which is comprised 4 key core clock proteins (circadian locomotor output cycles protein kaput, brain and muscle Arnt [Aryl hydrocarbon receptor nuclear translocator-like protein 1]-like protein 1, period, and cryptochrome; Figure 1). CLOCK (and its paralogue neuronal PAS [Per Arnt Sim] domain protein 2) and BMAL1 (also known as aryl hydrocarbon receptor nuclear translocator-like protein 1) heterodimerize and bind E-box

Correspondence to: Michelle L. Gumz, University of Florida, 1600 SW Archer Rd, Box 100224, Gainesville, FL 32610. Email michelle.gumz@medicine.ufl.edu
For Sources of Funding and Disclosures, see page 1193.

© 2021 American Heart Association, Inc.

Hypertension is available at www.ahajournals.org/journal/hyp

Nonstandard Abbreviations and Acronyms

ACE	angiotensin-converting enzyme
ARB	angiotensin receptor blocker
BP	blood pressure
CKD	chronic kidney disease
HARMONY	Hellenic-Anglo Research Into Morning or Night Antihypertensive Drug Delivery
IGF	insulin-like growth factor
IL	interleukin
PA	primary aldosteronism
PVAT	perivascular adipose tissue
SCN	suprachiasmatic nucleus
TIME	Treatment in Morning Versus Evening

response elements within promoter regions of target genes, including *period* and *cryptochrome* (encoding PER1/2/3 and CRY1/2, respectively), and retinoic acid-related orphan receptors and nuclear receptor subfamily 1 group D member (encoding ROR $\alpha/\beta/\gamma$ and REV-ERB α/β , respectively). In the negative feedback loops, PER and CRY heterodimerize and repress the activity of BMAL1 and CLOCK. ROR and REV-ERB mediate opposing actions on *Bmal1* gene expression.¹² Preclinical research has established that these circadian clock proteins regulate 43% of all expressed genes in mice,¹³ with >80% of protein-coding genes displaying 24-hour rhythms in expression in nonhuman primates.¹⁴ Work by various investigators using knockout rodent models of these core clock genes has brought us closer to understanding how the circadian mechanism contributes to BP regulation. However, the mechanisms underlying nondipping and abnormally elevated nocturnal BP remain to be fully elucidated.

The purpose of this review is to summarize the most recent advances in both basic and clinical research relating to circadian rhythms, clock genes, and hypertension. Furthermore, we highlight the adverse outcomes of altered circadian rhythm of BP in hypertension and consider future directions from these important findings.

ADVERSE OUTCOMES OF A NONDIPPING BP PROFILE

High nocturnal BP is often accompanied by a nondipping profile, but both independently have significance for target organ damage, particularly cardiovascular and renal damage. This has been evident in recent basic and clinical studies published between 2020 and 2021. Wang et al¹⁵ assessed isolated nocturnal hypertension in patients with CKD (n=1484) and found a high proportion of these individuals were nondippers (individuals with nocturnal systolic hypertension, 86%; nocturnal diastolic, 71%; and nocturnal systolic-diastolic, 86%). Interestingly,




Figure 1. Core components of the circadian clock.

CLOCK and BMAL1 heterodimerize and bind E-box response elements within promoter regions of target genes, including period and cryptochrome (encoding PER1/2/3 and CRY1/2, respectively). In the negative feedback loops, PER and CRY heterodimerize and repress the activity of BMAL1 and CLOCK. This clock mechanism regulates tissue-specific target genes to regulate many physiological processes. Diagram created with Biorender.com.

there was a higher prevalence of nondipping with nocturnal systolic and nocturnal systolic-diastolic hypertension. Furthermore, they observed an association between nocturnal systolic hypertension, either alone or in combination with nocturnal diastolic hypertension, and increased risk for cardiovascular events and renal failure in patients with CKD. Nondipping BP has also been associated with proteinuria and progression of renal injury in a rat model of salt-sensitive hypertension.¹⁶ In support of this, Cho et al reported that patients with controlled hypertension, described in this study as BP managed within a normal range (<140/90 mm Hg) by antihypertensive treatment, who were reverse dippers/nondippers had an increased risk of albuminuria and decreased renal function compared with normal/extreme dippers. Therefore, suggesting monitoring diurnal and nocturnal BP may predict CKD progression, which has been previously reported by Timio et al¹⁷ and Davidson et al.⁷ However, a limitation of these studies described above was that ambulatory BP was only measured for one 24-hour period. One 24-hour recording with BP measurements at 30 minutes intervals with $\geq 70\%$ of expected measurements (20 valid wake [9 AM–9 PM] and 7 valid asleep [1 AM–6 AM]) has been reported to validate ambulatory BP data. However, for research purposes, ≥ 2 valid daytime and 1 valid nighttime measurement per hour have been advised.¹⁸

Primary aldosteronism (PA) is reported in 5% to 10% of patients with hypertension. Patients with PA have been shown to be at high risk of left ventricular hypertrophy due to excessive aldosterone which is at least partly BP independent.¹⁹ Although, BP rhythm in PA has only been recently investigated by Wu et al who demonstrated that patients with PA (n=385) had higher nocturnal systolic BP, along with a nondipping pattern, compared with patients with

essential hypertension (n=385). This nondipping profile was suggested to be due to excessive aldosterone. There was no difference between age, sex, body mass index, 24-hour BP, daytime BP, or duration of hypertension between these groups. Importantly, the higher nocturnal systolic BP was strongly associated with cardiac damage in PA compared with patients with essential hypertension, emphasizing the importance of measuring ambulatory BP in this case.²⁰

In contrast, the STANISLAS cohort study (familial longitudinal population-based cohort from the Nancy region of France) did not find an association between nondipping BP profile (in patients with normotension or hypertension) and increased cardiovascular or renal damage.²¹ Normotensive and hypertensive individuals who were nondippers showed no differences between cardiovascular and renal parameters (including carotid intima-media thickness, pulse-wave velocity, left ventricular mass index, left ventricular hypertrophy, estimated glomerular filtration rate, microalbuminuria, and albuminuria/creatinine ratio) compared with their dipper counterparts.²¹ However, the mean 24-hour ambulatory BP in the hypertensive participants was <130/90 mmHg. Thus, this group is representative of controlled hypertension by antihypertensive treatment, and the lack of an association between nondipping BP and detrimental cardiorenal outcomes could be dependent on the level of BP control and whether the individual is truly hypertensive (>130/90 mmHg). It could be hypothesized that good BP control even in patients with nondipping hypertension could overcome the potential adverse effects of nondipping BP on target organ damage.

Many studies support this association that nocturnal systolic BP increases the risk of a decline in renal function and increased risk for cardiovascular events,^{22–25} for an extensive review on this association, see Hansen et al.²⁶ Although differing results have been reported from these studies regarding the link between the nondipping profile and worsening cardiorenal outcomes. There were no differences in the mean age range (between 50 and 70) in these studies. However, in Redon et al,²² where nondipping was not associated with worsening of cardiorenal outcomes, the enrolled participant number was far smaller than other studies and had a shorter follow-up period. The association between nondipping BP and target organ damage remains controversial due to the populations studied, sample size, and the assessment of specific target organ damage. There is a need for larger analysis addressing the potential association between nondipping BP and target organ damage, involving ambulatory BP measurements over a longer period of time in a variety of populations spanning various age groups and taking into account whether their hypertension is managed. This is essential to clarify the influence of ethnicity, age, and antihypertensive treatment on the predictive value of nondipping BP. Overall, these studies highlight the importance of monitoring nocturnal BP and BP rhythm using ambulatory BP measurements and nocturnal BP control for reducing the risk of target organ damage.

A ROLE FOR PERIPHERAL CLOCKS IN REGULATING BP RHYTHM

Smooth Muscle

The mechanisms regulating BP rhythm are not fully understood. Numerous studies have examined the role of circadian clocks using rodent models of null core clock gene mutations, with a particular interest in *BMAL1*. Male global *Bmal1* knockout mice exhibit nonrising BP during the active period, resulting in an overall lower 24-hour BP and loss of diurnal BP rhythm.²⁷ Efforts have been made to explore the tissue-specific mechanisms underlying the nonrising BP phenotype. Xie et al demonstrated that smooth muscle BMAL1 was essential for time-of-day variations in phenylephrine- and serotonin-induced vasoconstriction of renal and mesenteric arteries thought to reflect the dampened BP rhythm in smooth muscle-specific *Bmal1* knockout male mice.²⁸ The rhythmicity of the central clock in the SCN remained intact. Although, the extent of the loss of the diurnal BP rhythm was less than the global knockout, raising the question—what else is contributing to this nonrising phenotype? It remains unknown what the effect of *Bmal1* deletion in smooth muscle of female mice is.

Perivascular Adipose Tissue

Perivascular adipose tissue (PVAT) regulates vascular tone via contractile and anticontractile effects and has been shown to modulate BP in vivo, reviewed in Saxton et al²⁹ and Chang et al.³⁰ Chang et al³¹ investigated the role of the PVAT clock on BP regulation, specifically in brown adipocyte-specific *Bmal1* knockout male mice. These mice also had altered expression of other clock genes, including increased *Cry1* and *Npas2*, with decreases in *Per3* and *Rev-erba*. Brown adipocyte-specific *Bmal1* knockout male mice displayed reduced daytime BP, resulting in an extreme-dipper phenotype. The mechanisms behind this are thought to be via BMAL1 regulating transcription of angiotensinogen, leading to increases in angiotensin II levels in PVAT which act on smooth muscle cells within the vasculature to regulate vascular tone and BP rhythm.³¹ Again, it is unknown what the role of PVAT BMAL1 in females is, which merits investigation. Obesity is known to cause increased PVAT mass and PVAT dysfunction, which correlates with increased BP (reviewed in Xia and Li³²). Therefore, it would be of interest to investigate whether the PVAT clock is altered in animal models of obesity and if this impacts BP rhythm.

Liver

Patients with type 2 diabetes have an increased prevalence of BP rhythm disruption, with up to 70% reported as nondippers in a cross-sectional study of 20 000 patients with diabetes, and a role of the circadian clock has been indicated in the pathogenesis of diabetes.^{33,34}

Although little is known about the role of the clock genes in disruption of BP rhythm in diabetes. Hou et al used the db/db mouse (shown to have a nondipping phenotype³⁵) crossed with PERIOD2::LUCIFERASE knockin mouse to measure PER2 protein oscillation by bioluminescence in a diabetic mouse model.³⁶ These diabetic mice were also nondippers which was suggested to, in part, be due to the advanced phase shift of PER2 in peripheral tissues including the liver, as well as the kidney, and not the central clock in the SCN. Limited studies have explored whether specifically the liver circadian clock plays a role in BP regulation. A recent study has shown altered PVAT-mediated endothelial vascular function in hepatic-specific *Bmal1* knockout male mice, with lower systolic BP during the inactive period but no changes in either diastolic BP or heart rate.³⁷ This was thought to be due to changes in circulating levels of liver-derived mediators, including beta-hydroxybutyrate and IGF (insulin-like growth factor)-1.

Adrenal Gland

A previous study found an adrenal disorder, characterized by *Hsd3b6*-dependent aldosterone overproduction and differing aldosterone rhythm, in global double *Cry1/2* knockout mice compared with controls, which caused these mice to display salt-sensitive hypertension.³⁸ Whether BP rhythm was affected in these mice and if this is associated with the adrenal clock remains in question. However, it emphasizes the importance of maintenance of daily expression of adrenal *Hsd3b6* by the circadian clock in BP control and its response to a dietary salt challenge. A more recent study by Tanaka et al³⁹ investigated the role of the adrenal gland circadian clock in spontaneous hypertensive rats. Several adrenal gland circadian clock genes, such as *Bmal1*, *Per2*, *Per3*, and *Cry1*, were phase advanced compared with control rats. A major role of the adrenal gland is the steroidogenesis of glucocorticoids, mineralocorticoids, and androgens. The circadian expression profile of *steroidogenic acute regulatory protein*, the rate-limiting enzyme for steroidogenesis, was also found to be phase advanced, as well as serum corticosterone and aldosterone.³⁹ Both of these steroids have been implicated in BP rhythm.^{20,40} This study was observational so further research into the direct effect of the adrenal gland circadian clock on BP rhythmicity would be of interest.

Kidney

Numerous studies have examined the role of the intrinsic renal circadian clock in renal sodium handling to better understand its contributions to BP rhythm. For an excellent and extensive review on the role of the central/renal clock and reactive systems in regulating the rhythm of

renal sodium reabsorption to influence BP rhythm, see Ily et al.⁴¹ As previously mentioned, global *Bmal1* knockout mice are nonrisers,²⁷ which could be due, in part, to smooth muscle BMAL1.²⁸ The global *Bmal1* knockout mice also exhibited a loss in diurnal sodium excretion.⁴² Efforts have been made to explore the mechanisms behind the lost diurnal sodium excretion in global *Bmal1* knockout mice by using mouse models with deletions of *Bmal1* in different regions of the nephron of the kidney. Deleting *Bmal1* in the collecting duct of mice resulted in lowered BP but with no changes in either the diurnal rhythm of BP or sodium excretion. Furthermore, this phenotype was only seen in males, with females protected.⁴² This finding was supported by our own study where we generated a distal nephron-specific *Bmal1* knockout mouse model and found lowered BP, with no changes in rhythmicity, in a sex-dependent manner.⁴³ However, we did find that male mice had reduced renal sodium retention when challenged with a potassium-restricted diet.⁴³ Overall, suggesting BMAL1 in the distal portions of the kidney of mice contribute to BP regulation independent of changes in BP rhythm in a sex-dependent manner.

Overall, still little is known about the contribution of BMAL1 on diurnal control of renal sodium handling. Using a global *Bmal1* knockout rat, Johnston et al found that male *Bmal1* knockout rats had lost the diurnal rhythm of sodium excretion, although BP rhythm was intact⁴⁴ (unlike the *Bmal1* knockout mouse). Like previous studies, females were protected from this phenotype. This suggests BMAL1 is important for the control of diurnal sodium excretion, specifically in male rats, which interestingly appeared dissociated from BP rhythm.

There appears to be species differences with the role of BMAL1, increasing the complexity of understanding its contribution to BP control and rhythm. However, what has been continually reported is that females are protected from BP and renal sodium handling changes in *Bmal1* knockout rodent models. This has also been demonstrated in female *Per1* knockout mice.⁴⁵ This leads to questioning whether ovarian sex hormones play a role in the protection of this phenotype. Premenopausal women have a reduced prevalence of hypertension than men and are less likely to present with blunted BP rhythm.^{46–48} The prevalence for nondipping BP was 16 times higher in postmenopausal, compared with premenopausal woman.⁴⁹ Therefore, future work to explore the role of ovarian sex hormones in BP rhythm would be of interest.

An alternative approach was conducted by Murata et al⁵⁰ where they suggested the potential contribution of renal clock-regulated proteins, fragile X mental retardation syndrome-related protein 1 and phosphoribosyl pyrophosphate amidotransferase, in BP rhythm in spontaneous hypertensive rats.⁵⁰ FXR1 gene and protein levels were reduced in spontaneous hypertensive rats compared with Wistar Kyoto rats as controls, which was suggested to impact the proliferation and growth of renal

tubular cells. *Ppat* expression was increased in these rats, with no changes in protein levels, and has been linked with vascular toxicity via altering uric acid metabolism. This study was speculative in the role of FXR1 and PPAT in the diurnal variation of electrolyte and water handling, impacting BP rhythm. A caveat of this study was that the spontaneous hypertensive rats model does not have an appropriate genetic control. Wistar Kyoto rats are often used as controls for this model, as they were derived from the same colony as the spontaneous hypertensive rats. However, it has been reported that Wistar Kyoto rats may not constitute a single inbred strain.⁵¹ Future studies would be necessary to determine a causal link between altered FXR1 and PPAT levels and disruption of BP circadian rhythm and assess strain to strain variability. Furthermore, whether this is sex dependent would be of interest as the sex of the rats was not provided.

Together, these studies provide evidence for the potential role of the peripheral clock in the regulation of BP rhythm and for disruption of peripheral clock genes contributing to the nondipping BP pattern. However, this illustrates the complexity of control of BP rhythm and that, like the pathogenesis of hypertension, this likely involves complex crosstalk between these multiple systems and neurohormonal controllers.

REGULATING BP RHYTHM: THE TIMING OF FOOD INTAKE

The central clock receives light input directly from the retina for entrainment of time-of-day and remains resistant to phase perturbations from internal cues, unlike peripheral clocks that are susceptible to adjustments to reflect local metabolic demand (reviewed in Partch et al⁵²). Peripheral clocks have been shown to be entrained by food cues. The question remains, are light and food cues important for the circadian rhythm of BP? Zhang et al⁵³ addressed this by restricted feeding mice during their inactive phase, causing the BP rhythm to be inverted with no change in average 24-hour BP. Food consumption, over light, entrained BP rhythm in mice as their BP peak was during the feeding period even when fed at various times in constant darkness. Furthermore, the rhythm of *PER2* was assessed in tissues following restricted feeding, using the *PERIOD2::LUCIFERASE* knockin mouse. *PER2* in the SCN (central clock) was not affected, but restricted feeding caused a phase shift in the liver, renal inner medulla, and adrenal gland peripheral clocks. Changes in metabolism via restricted feeding have been previously shown to uncouple peripheral clocks from the central clock in the SCN.⁵⁴ Interestingly, the timing of food intake did not entrain renal excretion in mice as urine volume and sodium excretion were unaffected, suggesting a dissociation between BP rhythm and sodium excretion (previously discussed by Johnston

et al⁴⁴). These findings were shown to be independent of *BMAL1*. However, the role of other clock genes still needs to be explored. This study also observed an inactive phase (day) surge in plasma insulin and an overall increase in inactive phase plasma leptin compared with the active phase in restricted feeding. The contribution of increased nocturnal plasma insulin and leptin levels to the diurnal BP pattern warrants investigation.

What are the implications of this for human health? The benefits of time-restricted feeding (or intermittent fasting) have focused on weight loss, but recently, more benefits have been discovered that are dependent on the time-of-day of the feeding window. As previously mentioned, type 2 diabetic individuals have an increased prevalence of BP rhythm disruption^{32,33} along with sleep disturbances,⁵⁵ possibly, in part, due to clock gene rhythm disruptions.³⁵ In db/db mice, restricted feeding to the active phase (between 10 AM and 6 PM) improved their sleep-wake cycle and suggested sleep homeostatic function improvement.⁵⁶ Eating during a 6-hour period during the daytime, with a diet provided to ensure maintenance of body weight, in prediabetic men with their last meal consumed before 3 PM (to align with circadian rhythms of metabolism) has been shown to improve insulin sensitivity and lower BP, although BP rhythm was not assessed.⁵⁷ This lowering of BP was supported by another study following 10-hour restricted feeding in both male and female metabolic syndrome patients.⁵⁸ These participants were not restricted to what they could eat during this time and were instructed to continue their regular diet, which had to be recorded during this study. Sex differences were not explored in either of these studies. Interestingly, restricted feeding to the late afternoon/evening, with a diet to ensure maintenance of body weight, increased BP.⁵⁹ These studies highlight the potential benefits of time-restricted feeding, specifically during the day, on BP regulation, as well as sleep-wake cycles and insulin sensitivity. However, these studies did not assess the effect of time-restricted feeding on BP rhythm. Therefore, future work in determining the effect of restricted food consumption late at night/during the night compared to during the day on BP rhythm and nocturnal BP changes in both men and women would be of interest, especially for shift workers.

WHAT CAN YOUR GUT TELL YOU ABOUT BP RHYTHM?

Recent evidence has highlighted a relationship between the circadian clock and the gut microbiota—where the circadian clock can modulate the composition and time-of-day variation of gut microbiota, and microbiota can contribute to the maintenance of clock function (reviewed in Murakami and Tognini⁶⁰). Diurnal changes in the composition and function of the gut microbiota can be modulated by time of feeding and diet,^{61,62} and diurnal

oscillations are abolished in certain gut microbiota in global *Bmal1* knockout mice which were sex dependent.⁶³ Gut microbiota dysbiosis has been shown to contribute to the development of hypertension.⁶⁴ Chakraborty et al⁶⁵ hypothesized that diurnal alterations in gut microbial composition could contribute to a salt-sensitive hypertensive phenotype. This study illustrated that the composition of microbial communities exhibits circadian rhythms that were aligned with BP rhythm in male Dahl salt-sensitive rats. This reshaping of microbiota could be an evolutionary adaptation to ensure the survival of bacterial species, increasing their ability to survive under differing food availability during a 24-hour period. However, it has been suggested that this reshaping alters microbial function, impacting the BP of the host. Furthermore, a high salt diet in these rats elicited a time-of-day variation in specific gut microbes.⁶⁵ Future work is needed to test a causal link between gut microbiota rhythm and BP variation. With the time of feeding impacting diurnal alterations in the gut microbiota, it would also be of interest to determine if the link between time of restricted feeding and BP rhythm (previously discussed) is associated with diurnal alterations in gut microbiota.

INFLAMMATION

The cellular clock is present in immune cells with many aspects of the immune response exhibiting daily oscillations. These oscillations of immune cell recruitment to tissues are thought to promote tissue recovery.⁶⁶ This has been implicated in a rat model of sepsis, where the absence of circadian light cues reduced survival compared with a 12-hour light/dark cycle.⁶⁷ This study raises the question of whether there would be a benefit of daily lighting cycles in intensive care units for improving the recovery of patients with sepsis. The circadian rhythm of the immune response can also impact disease development.⁶⁶ Clock gene expression has been linked to the expression of proinflammatory cytokines and implicated in the development of cancer.^{68,69} Over the last decade, there has been increasing evidence for the contribution of the immune system in the pathogenesis of hypertension, recently reviewed by Drummond et al.⁷⁰ Although little is known if there is a role for the clock in different immune cells in the regulation of BP rhythm. A recent study by Yang et al⁷¹ used a mouse model of myeloid cell-specific *Bmal1* deletion showed to have unaltered BP at Zeitgeber times 4 to 5 (\approx 11 AM, during the mouse rest phase), using tail-cuff system, and therefore, BP rhythm was not assessed.⁷¹ With previous studies implicating a link between circadian rhythms and the immune response, and the contribution of the immune system in hypertension, improved understanding of rhythms in the immune response and if these rhythms impact BP rhythms would be of great interest.

AUTONOMIC NERVOUS SYSTEM

Several studies have investigated the role of the autonomic nervous system in nondipping BP. Studies have suggested a failure to reduce sympathetic and increase parasympathetic activity contributes to a nondipping BP phenotype.^{72–74} However, patients with primary autonomic failure, so very low sympathetic and parasympathetic activities have a high incidence of nondipping.⁷⁵ This suggests that it is the lack of autonomic tone modulation that contributes to nondipping. The autonomic nervous system also plays a role in renal solute handling,⁷⁶ and it is postulated that this autonomic control of renal function plays a role in diurnal BP rhythms, although further work is needed to explore these interactions directly. This has been recently reviewed by Becker et al⁷⁷ and highlights future directions in this area, including the recognition of time-of-day, which can influence renal function and autonomic control outcomes.

RECENT AND ONGOING CHRONOTHERAPY CLINICAL TRIALS

Importantly, the majority (\approx 82%) of US Food and Drug Administration-approved drugs target the products of rhythmic genes found in the mouse¹³ and nonhuman primate,¹⁴ and therefore, there may be benefits of timed dosing. Theoretically, chronotherapy has the potential to offer these benefits, although many remain skeptical. The clinical relevance of chronotherapy has been demonstrated in rheumatoid arthritis, as administration of glucocorticoid treatment at night when IL (interleukin)-6 levels peak has been shown to improve the pronounced joint pain seen in the morning in these patients,⁷⁸ reduce inflammation and improve sleep quality (reviewed in Buttgereit et al⁷⁹). Furthermore, chronotherapy clinical trials with various cancer treatments, including oxaliplatin, 5-fluorouracil, and folinic acid in metastatic colorectal cancer,⁸⁰ have shown to be beneficial and less toxic. Over the last decade, Hermida et al have published several articles emphasizing the importance of ambulatory BP monitoring and demonstrating the cardiovascular benefits of nighttime dosing of antihypertensive drugs to patients with nondipping hypertension.^{81–83} A recent report of the Hygia Chronotherapy Trial (URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT00741585) has been published illustrating that routine ingestion of 1 or more antihypertensive drugs (ARB [angiotensin receptor blocker], ACE [angiotensin-converting enzyme] inhibitor, calcium channel blocker, β -blocker, and diuretic) at bedtime in patients with hypertension (n=9552) improved dipper profile and reduced the occurrence of major cardiovascular events, compared with ingestion upon awaking (n=9532).⁸⁴ However, limitations of this study were the use of the prospective, randomized, open-label, blinded-end point design, which

can create a source of bias as both the treating physician and participant are aware of their assigned group. Also, participants could be prescribed any and as many medications of the antihypertensive drug classes, potentially for treatment benefit over nighttime dosing benefit. Concerns have been raised over the effect size and conduct of this trial, and the *European Heart Journal* has reviewed and published these in the *Discussion Forum* in its April 21, 2020, issue, including responses from the investigators.^{85–92} It is also worth noting that the recent HARMONY trial (Hellenic-Anglo Research Into Morning or Night Antihypertensive Drug Delivery) showed no benefits of nighttime dosing with antihypertensive treatment,⁹³ see the Table. Furthermore, some studies have shown no benefits of nighttime dosing with specific antihypertensive treatment⁹⁵ or in specific ethnic groups.⁹⁶

Currently, the TIME clinical study (Treatment in Morning Versus Evening) (recruitment details published in Rorie et al^{94,97}) based in the United Kingdom is in progress, involving the prospective, randomized, open-label, blinded-end point-based design. Recruitment includes >20 000 participants already on antihypertensive treatment instructed to take their medication either in the

morning or at night over a 4-year period, with cardiovascular outcomes assessed. Although ambulatory BP monitoring will not be reported in this trial, and therefore unlikely to provide further evidence for a benefit for chronotherapy for hypertension. In the Effect of Antihypertensive Medication Timing on Morbidity and Mortality (BedMed) trial (URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT02990663), based in Alberta Canada, patients with hypertension (estimated n=3400) are again instructed to take their antihypertensive medication either in the morning or at night over an average of a 4-year period. Interestingly, the same group of investigators is completing a similar clinical trial as above, however, specifically in an elderly population of 1200 participants (BedMed Frail, URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT04054648). The completion of both BedMed trials is due by the end of 2022. Recent and ongoing clinical trials for chronotherapy in hypertension have been summarized in the Table.

There are studies, although with small sample sizes, that have explored morning versus evening dosing of specific antihypertensive drugs or combination antihypertensive therapy, reviewed in De Giorgi et al.⁹⁸ The bulk of these studies suggested benefits of evening

Table. Recent and In-Progress Clinical Trials for Chronotherapy in Hypertension

Clinical trial	Participant details	Duration	Study design	In progress?	Results	Reference
Hellenic-Anglo Research into Morning or Night Antihypertensive Drug Delivery (HARMONY; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01669928)	103 patients with hypertension (59 men/44 women, 61.8±10.3 y of age)	24 wk	Patients assigned to ingest ≥1 hypertension medication in the morning (6 AM–11 AM; n=51) or in the evening (6 PM–11 PM; n=52) for 12 wk then crossed over for remaining 12 wk. 24-h ambulatory BP monitoring.	No	No significant differences in 24 h, daytime, or nighttime SBP between morning and evening administration of antihypertensive medication.	Poulter et al ⁹³
Hygia chronotherapy (URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00741585)	19 084 patients with hypertension (10 614 men/8470 women, 60.5±13.7 y of age)	6.3 y median patient follow-up	Patients assigned to ingest ≥1 hypertension medication at bedtime (n=9552) or upon awakening (n=9532). 48 h ambulatory BP monitoring.	No	Reduced nighttime SBP, lower prevalence of non-dipping BP, and 45% reduction in primary cardiovascular disease outcome in bedtime ingestion patients, compared with morning dosing.	Hermida et al ⁹⁴
Treatment in Morning versus Evening (TIME; UKCRN1707)	21 116 patients with hypertension	4 y	Patients assigned to ingest ≥1 hypertension medication in the morning or evening. No ambulatory BP monitoring. Primary end point is hospitalization for the composite end point of nonfatal MI/stroke or vascular death.	Yes		Rorie et al ⁹⁴
Effect of Antihypertensive Medication Timing on Morbidity and Mortality (BedMed; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02990663)	3440 patients with hypertension (estimated enrollment)	4 y	Patients assigned to ingest ≥1 hypertension medication in the morning or evening.	Yes		
BedMed Frail (URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02990663)	1200 patients with hypertension who are residents in a participating long-term care facility (estimated enrollment)	2 y (estimate)	Patients assigned to ingest ≥1 hypertension medication in the morning or evening.	Yes		

BP indicates blood pressure; MI, myocardial infarction; and SBP, systolic blood pressure.

dosing over morning, but some highlighted benefits of morning administration or no differences with timing of dosage. These differences could relate to the specific pharmacokinetic profile of antihypertensive drugs. Therefore, the pharmacokinetics of drugs for chronotherapy need to be considered.⁹⁹ Previous studies have investigated the pharmacokinetic profile of antihypertensive drugs after morning or evening administration, reviewed in Hermida et al.¹⁰⁰ The calcium channel blocker, amlodipine, has been shown to have a shorter time to reach maximum plasma concentration (T_{max}), greater mean peak plasma concentration (C_{max}), and longer half-life after evening oral dosing compared with morning dosing in both normotensive and hypertensive subjects, indicating enhanced absorption of amlodipine when administered at night. This pharmacokinetic profile correlated with significant reductions in BP and heart rate in patients with hypertension following evening dosing.¹⁰¹ There have also been reports highlighting sex-specific differences in pharmacokinetics of antihypertensive drugs.^{102–104} For example, women have been shown to exhibit higher C_{max} to β -blockers metoprolol and propranolol due to increased absorption and slower clearance via CYP2D6.^{105,106}

Although these trials provide promise, uncertainty remains over the benefit of chronotherapy for hypertension, and larger trials across multiple ethnic groups with specific antihypertensive drug classes and gender differences investigated are needed to determine who will benefit from chronotherapy. If chronotherapy is not deemed to be superior to the current standard of care for hypertension, it may be beneficial in correcting loss of BP rhythm, which alone is a risk factor for cardiovascular mortality.¹⁰⁷ Overall, the optimal method to test chronotherapy in hypertension is using ambulatory BP monitoring and using drugs with half-lives that are appropriate for nighttime use.

SHIFT WORKING

Shift work, defined by working hours out with the typical working time of 7 AM to 6 PM, has been associated with increased risk of hypertension, as well as cardiovascular disease and type 2 diabetes.¹⁰⁸ A meta-analysis of 27 observational studies found a significant association between shift work and hypertension, especially in male shift workers. There was no association between specifically shift work at night, that is, the Graveyard shift, and a higher risk of hypertension, however, data for this were limited.¹⁰⁹ Although this was not the case when assessing the risk of hypertension in a cohort of 2151 workers from US shift/night workers in manufacturing facilities. Workers with mostly night work with frequent rotations had a 4-fold high risk for hypertension, with the highest rates of hypertension in individuals who worked 95% to 100% night work.¹¹⁰ Regarding the risk of CKD




Figure 2. Cellular circadian clocks throughout the body, entrained by food cues, contributing to the circadian rhythm of blood pressure (BP).

BP has a 24-h cycle, peaking during the day and dipping by 10%–20% during the night. Studies in rodents and humans suggest peripheral clocks within the vasculature, liver, adrenal glands, kidneys, microbiota in the gut, immune system, and autonomic nervous system contribute to regulation of the circadian rhythm of BP. These peripheral clocks can be entrained by food cues; therefore, time-of-day feeding could be important for BP rhythm. Dysregulation of the circadian rhythm of BP is associated with adverse cardiorenal outcomes and increased risk of cardiovascular mortality. There are ongoing clinical trials to determine if chronotherapy will be beneficial for hypertension management, and this should be expanded to whether it can correct any losses of BP rhythm. Diagram created with Biorender.com.

in shift workers, the Korea National Health and Nutrition Examination Survey study explored the association between shift work and CKD in both male and female manual labor daytime and shift workers ($n=3504$). This study illustrated female shift workers had an increased risk of CKD, with no association in male workers.¹¹¹ BP was measured in these individuals with no significant difference between daytime and shift workers. The BP rhythm was not assessed in these individuals. Hill et al¹¹² used a preclinical model to investigate how circadian disruption affects kidney function and found that shifting the light cycle to mimic shift work in male hypertensive rats disrupted rhythms in renal excretion and caused an acceleration of renal injury marker excretion. Whether this could influence the pathogenesis of hypertension and CKD remains to be explored.

There have been limited studies on the impact of acute or long-term shift work on BP rhythm. A recent meta-analysis of 50 publications between 1980 and 2018 revealed BP dipped during the sleep period in shift workers, but these studies varied widely of shift work type, shift schedules, and regularity of BP monitoring.¹¹³ Further research is needed to investigate the impact of acute and long-term shift work on ambulatory BP in shift workers with and without hypertension.

CONCLUSION AND FUTURE PERSPECTIVES

Together these findings prompt many ongoing questions. Whether nondipping BP worsens cardiorenal outcomes remains in debate, but the recent studies illustrated in this review have provided evidence for adverse outcomes in patients that have nondipping nocturnal hypertension. This was particularly evident in patients with CKD, suggesting the circadian BP profile could predict the progression of CKD. Therefore, highlighting the importance of monitoring 24-hour BP rhythm using ambulatory BP monitoring and that restoring a BP dip should be recognized as an important aspect of BP control. Although the mechanisms behind the circadian rhythm of BP are not fully understood, what is clear is that it involves multiple organ systems, illustrated in Figure 2. A better understanding of clock function in various peripheral clocks will help pave the way for targeted therapeutics in the treatment of hypertension. Time of feeding and what we are eating, which can affect our gut microbiota composition, could have long-term impacts on our BP rhythm. A consideration for future research would be whether the timing of the consumption of specific foods would have differing effects on BP. Does a higher salt load at night have implications on nondipping BP? Considering the findings regarding time-restricted feeding, it would be of interest to investigate whether the timing of the consumption of high salt meals at lunchtime rather than dinnertime had influences on BP. This would also be particularly relevant for shift workers where late-night eating is more common.

ARTICLE INFORMATION

Affiliations

Department of Physiology and Functional Genomics, Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, and Center for Integrative Cardiovascular and Metabolic Diseases, University of Florida, Gainesville.

Sources of Funding

This work was supported by R01DK109570 and American Heart Association Established Investigator Award to M.L. Gumz, R01DK123078 (M.L. Gumz co-investigator).

Disclosures

None.

REFERENCES

- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. Authors/Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;34:2159–2219.
- Whelton PK. Epidemiology of hypertension. *Lancet*. 1994;344:101–106. doi: 10.1016/s0140-6736(94)91285-8
- Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? *J Hypertens*. 2019;37:1148–1153. doi: 10.1097/HJH.0000000000002021
- Douma LG, Gumz ML. Circadian clock-mediated regulation of blood pressure. *Free Radic Biol Med*. 2018;119:108–114. doi: 10.1016/j.freeradbiomed.2017.11.024
- Giuseppe M, Gianfranco P. Ambulatory blood pressure monitoring and organ damage. *Hypertension*. 2000;36:894–900.
- Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, et al; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. *N Engl J Med*. 2003;348:2407–2415. doi: 10.1056/NEJMoa022273
- Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. *Arch Intern Med*. 2006;166:846–852. doi: 10.1001/archinte.166.8.846
- Mojón A, Ayala DE, Piñero L, Otero A, Crespo JJ, Moyá A, Bóveda J, de Lis JP, Fernández JR, Hermida RC; Hygia Project Investigators. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. *Chronobiol Int*. 2013;30:145–158. doi: 10.3109/07420528.2012.703083
- Li Y, Staessen JA, Lu L, Li LH, Wang GL, Wang JG. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. *Hypertension*. 2007;50:333–339. doi: 10.1161/HYPERTENSIONAHA.107.087767
- Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. *Hypertension*. 1994;24:793–801. doi: 10.1161/01.hyp.24.6.793
- De La Sierra A, Gorostidi M, Banegas JR, Segura J, De La Cruz JJ, Ruilope LM. Nocturnal hypertension or nondipping: Which is better associated with the cardiovascular risk profile? *Am J Hypertens*. 2014;27:680–687.
- Takahashi JS. Transcriptional architecture of the mammalian circadian clock. *Nat Rev Genet*. 2017;18:164–179. doi: 10.1038/nrg.2016.150
- Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. *Proc Natl Acad Sci USA*. 2014;111:16219–16224. doi: 10.1073/pnas.1408886111
- Mure LS, Le HD, Benegiamo G, Chang MW, Rios L, Jillani N, Ngotho M, Kariuki T, Dkhissi-Benyahya O, Cooper HM, et al. Diurnal transcriptome atlas of a primate across major neural and peripheral tissues. *Science*. 2018;359:eaao0318. doi: 10.1126/science.aao0318
- Wang Q, Wang Y, Wang J, Zhang L, Zhao MH; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE); Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE) Collaborators. Nocturnal systolic hypertension and adverse prognosis in patients with CKD. *Clin J Am Soc Nephrol*. 2021;16:356–364. doi: 10.2215/CJN.14420920
- Sufiun A, Rahman A, Rafiq K, Fujisawa Y, Nakano D, Kobara H, Masaki T, Nishiyama A. Association of a disrupted dipping pattern of blood pressure with progression of renal injury during the development of salt-dependent hypertension in rats. *Int J Mol Sci*. 2020;21:E2248. doi: 10.3390/ijms21062248
- Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, Guerrini E. “Nondipper” hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. *Clin Nephrol*. 1995;43:382–387.
- O'Brien E, Parati G, Stergiou G. Ambulatory blood pressure measurement: what is the international consensus? *Hypertension*. 2013;62:988–994. doi: 10.1161/HYPERTENSIONAHA.113.02148
- Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension*. 2013;62:331–336. doi: 10.1161/HYPERTENSIONAHA.113.01060
- Wu Q, Hong M, Xu J, Tang X, Zhu L, Gao P, Wang J. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism. *Endocrine*. 2021;72:835–843. doi: 10.1007/s12020-021-02606-3
- Lopez-Sublet M, Girerd N, Bozec E, Machu JL, Ferreira JP, Zannad F, Mourad JJ, Rossignol P. Nondipping pattern and cardiovascular and renal damage in a population-based study (The STANISLAS Cohort Study). *Am J Hypertens*. 2019;32:620–628. doi: 10.1093/ajh/hp020
- Redon J, Plancha E, Swift PA, Pons S, Muñoz J, Martínez F. Nocturnal blood pressure and progression to end-stage renal disease or death in nondiabetic chronic kidney disease stages 3 and 4. *J Hypertens*. 2010;28:602–607. doi: 10.1097/HJH.0b013e328333fe4d
- Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboli P, Conte G, Gabbai FB, et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. *Arch Intern Med*. 2011;171:1090–1098. doi: 10.1001/archinternmed.2011.230
- Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of

death and cause-specific cardiovascular events in hypertension. *Hypertension*. 2008;51:55–61. doi: 10.1161/HYPERTENSIONAHA.107.100727

25. Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P, Eguchi K, Kario K, Hoshida S, Polonia J, et al; ABC-H Investigators. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. *Hypertension*. 2016;67:693–700. doi: 10.1161/HYPERTENSIONAHA.115.06981
26. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. *Hypertension*. 2011;57:3–10. doi: 10.1161/HYPERTENSIONAHA.109.133900
27. Curtis AM, Cheng Y, Kapoor S, Reilly D, Price TS, Fitzgerald GA. Circadian variation of blood pressure and the vascular response to asynchronous stress. *Proc Natl Acad Sci USA*. 2007;104:3450–3455. doi: 10.1073/pnas.0611680104
28. Xie Z, Su W, Liu S, Zhao G, Esser K, Schroder EA, Lefta M, Stauss HM, Guo Z, Gong MC. Smooth-muscle BMAL1 participates in blood pressure circadian rhythm regulation. *J Clin Invest*. 2015;125:324–336. doi: 10.1172/JCI76881
29. Saxton SN, Clark BJ, Withers SB, Eringa EC, Heagerty AM. Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue. *Physiol Rev*. 2019;99:1701–1763. doi: 10.1152/physrev.00034.2018
30. Chang L, Garcia-Barrio MT, Chen YE. Perivascular adipose tissue regulates vascular function by targeting vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*. 2020;40:1094–1109. doi: 10.1161/ATVBAHA.120.312464
31. Chang L, Xiong W, Zhao X, Fan Y, Guo Y, Garcia-Barrio M, Zhang J, Jiang Z, Lin JD, Chen YE. Bmal1 in perivascular adipose tissue regulates resting-phase blood pressure through transcriptional regulation of angiotensinogen. *Circulation*. 2018;138:67–79. doi: 10.1161/CIRCULATIONAHA.117.029972
32. Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. *Br J Pharmacol*. 2017;174:3425–3442. doi: 10.1111/bph.13650
33. Gorostidi M, Sobrino J, Segura J, Sierra C, de la Sierra A, Hernández del Rey R, Vinyoles E, Galcerán JM, López-Eady MD, Marín R, et al; Spanish Society of Hypertension ABPM Registry investigators. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. *J Hypertens*. 2007;25:977–984. doi: 10.1097/HJH.0b013e32809874a2
34. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. *Science*. 2010;330:1349–1354. doi: 10.1126/science.1195027
35. Su W, Guo Z, Randall DC, Cassis L, Brown DR, Gong MC. Hypertension and disrupted blood pressure circadian rhythm in type 2 diabetic db/db mice. *Am J Physiol Regul Integr Comp Physiol*. 2008;295:H1634–H1641. doi: 10.1152/ajpheart.00257.2008
36. Hou T, Su W, Guo Z, Gong MC. A novel diabetic mouse model for real-time monitoring of clock gene oscillation and blood pressure circadian rhythm. *J Biol Rhythms*. 2019;34:51–68. doi: 10.1177/0748730418803719
37. Pati P, Valcin JA, Zhang D, Neder TH, Millender-Swain T, Allan JM, Sedaka R, Jin C, Becker BK, Pollock DM, et al. Liver circadian clock disruption alters perivascular adipose tissue gene expression and aortic function in mice. *Am J Physiol Regul Integr Comp Physiol*. 2021;320:R960–R971. doi: 10.1152/ajpregu.00128.2020
38. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. *Nat Med*. 2010;16:67–74. doi: 10.1038/nm.2061
39. Tanaka S, Ueno T, Tsunemi A, Nagura C, Tahira K, Fukuda N, Soma M, Abe M. The adrenal gland circadian clock exhibits a distinct phase advance in spontaneously hypertensive rats. *Hypertens Res*. 2019;42:165–173. doi: 10.1038/s41440-018-0148-8
40. Ivy JR, Oosthuyzen W, Peltz TS, Howarth AR, Hunter RW, Dhaun N, Al-Dujaili EA, Webb DJ, Dear JW, Flatman PW, et al. Glucocorticoids induce nondipping blood pressure by activating the thiazide-sensitive cotransporter. *Hypertension*. 2016;67:1029–1037. doi: 10.1161/HYPERTENSIONAHA.115.06977
41. Ivy JR, Bailey MA. Nondipping blood pressure: predictive or reactive failure of renal sodium handling? *Physiology (Bethesda)*. 2021;36:21–34. doi: 10.1152/physiol.00024.2020
42. Zhang D, Jin C, Obi E, Rhoads MK, Soliman RH, Sedaka RS, Allan JM, Tao B, Speed JS, Pollock JS, et al. Loss of circadian gene Bmal1 in the collecting duct lowers blood pressure in male, but not female, mice. *Am J Physiol Renal Physiol*. 2020;318:F710–F719. doi: 10.1152/ajprenal.00364.2019
43. Crislip GR, Douma LG, Masten SH, Cheng KY, Lynch JJ, Johnston JG, Barral D, Glasford KB, Holzworth MR, Verlander JW, et al. Differences in renal BMAL1 contribution to Na⁺ homeostasis and blood pressure control in male and female mice. *Am J Physiol Renal Physiol*. 2020;318:F1463–F1477. doi: 10.1152/ajprenal.00014.2020
44. Johnston JG, Speed JS, Becker BK, Kasztan M, Soliman RH, Rhoads MK, Tao B, Jin C, Geurts AM, Hyndman KA, et al. Diurnal control of blood pressure is uncoupled from sodium excretion. *Hypertension*. 2020;75:1624–1634. doi: 10.1161/HYPERTENSIONAHA.119.13908
45. Douma LG, Solocinski K, Holzworth MR, Crislip GR, Masten SH, Miller AH, Cheng KY, Lynch JJ, Cain BD, Wingo CS, et al. Female C57BL/6J mice lacking the circadian clock protein PER1 are protected from nondipping hypertension. *Am J Physiol Regul Integr Comp Physiol*. 2019;316:R50–R58. doi: 10.1152/ajpregu.00381.2017
46. Sherwood A, Thurston R, Steffen P, Blumenthal JA, Waugh RA, Hinderliter AL. Blunted nighttime blood pressure dipping in postmenopausal women. *Am J Hypertens*. 2001;14(8 pt 1):749–754. doi: 10.1016/s0895-7061(01)02043-x
47. Perez-Lloret S, Toblli JE, Cardinali DP, Milei J. Gender differences in age-related increase of asleep blood pressure. *Arch Gerontol Geriatr*. 2010;50:319–322. doi: 10.1016/j.archger.2009.05.005
48. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. *Circulation*. 2018;137:109–118. doi: 10.1161/CIRCULATIONAHA.117.032582
49. Routledge FS, McFetridge-Durdle JA, Dean CR. Stress, menopausal status and nocturnal blood pressure dipping patterns among hypertensive women. *Can J Cardiol*. 2009;25:e157–e163. doi: 10.1016/s0828-282x(09)70089-3
50. Murata Y, Ueno T, Tanaka S, Kobayashi H, Okamura M, Hemmi S, Fuke Y, Matsumoto Y, Abe M, Fukuda N. Identification of clock genes related to hypertension in kidney from spontaneously hypertensive rats. *Am J Hypertens*. 2020;33:1136–1145. doi: 10.1093/ajh/hpaa123
51. Kurtz TW, Morris RC Jr. Biological variability in Wistar-Kyoto rats. Implications for research with the spontaneously hypertensive rat. *Hypertension*. 1987;10:127–131. doi: 10.1161/01.hyp.10.1.127
52. Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. *Trends Cell Biol*. 2014;24:90–99. doi: 10.1016/j.tcb.2013.07.002
53. Zhang D, Colson JC, Jin C, Becker BK, Rhoads MK, Pati P, Neder TH, King MA, Valcin JA, Tao B, et al. Timing of food intake drives the circadian rhythm of blood pressure. *Function (Oxf)*. 2021;2:zqaa034. doi: 10.1093/function/zqaa034
54. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes Dev*. 2000;14:2950–2961. doi: 10.1101/gad.183500
55. Nakanishi-Minami T, Kishida K, Funahashi T, Shimomura I. Sleep-wake cycle irregularities in type 2 diabetics. *Diabetol Metab Syndr*. 2012;4:18. doi: 10.1186/1758-5996-4-18
56. Hou T, Wang C, Joshi S, O'Hara BF, Gong MC, Guo Z. Active time-restricted feeding improved sleep-wake cycle in db/db mice. *Front Neurosci*. 2019;13:1–10. doi: 10.3389/fnins.2019.00969
57. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. *Cell Metab*. 2018;27:1212–1221.e3. doi: 10.1016/j.cmet.2018.04.010
58. Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, Wang X, Fleischer JG, Navlakha S, Panda S, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. *Cell Metab*. 2020;31:92–104.e5. doi: 10.1016/j.cmet.2019.11.004
59. Stote KS, Baer DJ, Spears K, Paul DR, Harris GK, Rumpel WV, Strycula P, Najjar SS, Ferrucci L, Ingram DK, et al. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. *Am J Clin Nutr*. 2007;85:981–988. doi: 10.1093/ajcn/85.4.981
60. Murakami M, Tognini P. The circadian clock as an essential molecular link between host physiology and microorganisms. *Front Cell Infect Microbiol*. 2019;9:469. doi: 10.3389/fcimb.2019.00469
61. Zarrinpar A, Chaix A, Yooseph S, Panda S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. *Cell Metab*. 2014;20:1006–1017. doi: 10.1016/j.cmet.2014.11.008
62. Thaïs CA, Zeevi D, Levy M, Zilberman-Schapira G, Suez J, Tengeler AC, Abramson L, Katz MN, Korem T, Zmora N, et al. Transkingdom control

- of microbiota diurnal oscillations promotes metabolic homeostasis. *Cell*. 2014;159:514–529. doi: 10.1016/j.cell.2014.09.048
63. Liang X, Bushman FD, Fitzgerald GA. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock. *Proc Natl Acad Sci USA*. 2015;112:10479–10484. doi: 10.1073/pnas.1501305112
 64. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM Jr, Durgan DJ. Alterations in the gut microbiota can elicit hypertension in rats. *Physiol Genomics*. 2017;49:96–104. doi: 10.1152/physiolgenomics.00081.2016
 65. Chakraborty S, Mandal J, Cheng X, Galla S, Hindupur A, Saha P, Yeoh BS, Mell B, Yeo JY, Vijay-Kumar M, et al. Diurnal timing dependent alterations in gut microbial composition are synchronously linked to salt-sensitive hypertension and renal damage. *Hypertension*. 2020;76:59–72. doi: 10.1161/HYPERTENSIONAHA.120.14830
 66. Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. *Nat Rev Immunol*. 2013;13:190–198. doi: 10.1038/nri3386
 67. Carlson DE, Chiu WC. The absence of circadian cues during recovery from sepsis modifies pituitary-adrenocortical function and impairs survival. *Shock*. 2008;29:127–132. doi: 10.1097/shk.0b013e318142c5a2
 68. Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM. Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. *Proc Natl Acad Sci USA*. 2012;109:12662–12667. doi: 10.1073/pnas.1209965109
 69. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene *Period2* plays an important role in tumor suppression and DNA damage response in vivo. *Cell*. 2002;111:41–50. doi: 10.1016/s0092-8674(02)00961-3
 70. Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. *Nat Rev Immunol*. 2019;19:517–532. doi: 10.1038/s41577-019-0160-5
 71. Yang G, Zhang J, Jiang T, Monslow J, Tang SY, Todd L, Puré E, Chen L, Fitzgerald GA. Bmal1 deletion in myeloid cells attenuates atherosclerotic lesion development and restrains abdominal aortic aneurysm formation in hyperlipidemic mice. *Arterioscler Thromb Vasc Biol*. 2020;40:1523–1532. doi: 10.1161/ATVBAHA.120.314318
 72. Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. *Hypertension*. 1995;26:808–814. doi: 10.1161/01.hyp.26.5.808
 73. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. *Am J Hypertens*. 2002;15(2 pt 1):111–118. doi: 10.1016/s0895-7061(01)02251-8
 74. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. *Hypertension*. 2008;52:925–931. doi: 10.1161/HYPERTENSIONAHA.108.116368
 75. Mann S, Altman DG, Raftery EB, Bannister R. Circadian variation of blood pressure in autonomic failure. *Circulation*. 1983;68:477–483. doi: 10.1161/01.cir.68.3.477
 76. Johns EJ, Kopp UC, DiBona GF. Neural control of renal function. *Compr Physiol*. 2011;1:731–767. doi: 10.1002/cphy.c100043
 77. Becker BK, Zhang D, Soliman R, Pollock DM. Autonomic nerves and circadian control of renal function. *Auton Neurosci*. 2019;217:58–65. doi: 10.1016/j.autneu.2019.01.003
 78. Arvidson NG, Gudbjörnsson B, Larsson A, Hållgren R. The timing of glucocorticoid administration in rheumatoid arthritis. *Ann Rheum Dis*. 1997;56:27–31. doi: 10.1136/ard.56.1.27
 79. Buttgerit F, Smolen JS, Coogan AN, Cajochen C. Clocking in: chronobiology in rheumatoid arthritis. *Nat Rev Rheumatol*. 2015;11:349–356. doi: 10.1038/nrrheum.2015.31
 80. Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. *Lancet*. 1997;350:681–686. doi: 10.1016/s0140-6736(97)03358-8
 81. Ayala DE, Hermida RC, Mojón A, Fernández JR. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. *Chronobiol Int*. 2013;30:340–352. doi: 10.3109/07420528.2012.701455
 82. Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. *J Am Coll Cardiol*. 2011;58:1165–1173. doi: 10.1016/j.jacc.2011.04.043
 83. Hermida RC, Smolensky MH, Ayala DE, Portaluppi F, Crespo JJ, Fabbian F, Haus E, Manfredini R, Mojón A, Moyá A, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. *Chronobiol Int*. 2013;30:355–410. doi: 10.3109/07420528.2013.750490
 84. Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, Sineiro E, Castiella MC, Callejas PA, Pousa L, et al; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. *Eur Heart J*. 2020;41:4565–4576. doi: 10.1093/eurheartj/ehz754
 85. Guthrie G, Poulter N, Macdonald T, Ford I, Mackenzie I, Findlay E, Williams B, Brown M, Lang C, Webb D. Chronotherapy in hypertension: the devil is in the details. *Eur Heart J*. 2020;41:1606–1607. doi: 10.1093/eurheartj/ehaa265
 86. Relates to: 'bedtime hypertension treatment improves cardiovascular risk reduction: hygia chronotherapy trial'. *Eur Heart J*. 2020;41:1600. doi: 10.1093/eurheartj/ehaa339
 87. Lüscher TF. The Hygia trial: Discussions about surprising results. *Eur Heart J*. 2020;41:1600. doi: 10.1093/eurheartj/ehaa274
 88. Sánchez-Sánchez C, López-Caballero C, Contreras I, Puerto B, Blázquez-Bermejo Z. Is bedtime treatment appropriate for all hypertensive patients? *Eur Heart J*. 2020;41:1604. doi: 10.1093/eurheartj/ehaa212
 89. Şen S, Kaşkal M, Üresin Y. Chrono-pharmacological effects of antihypertensive drugs. *Eur Heart J*. 2020;41:1601. doi: 10.1093/eurheartj/ehaa213
 90. Hermida RC, Mojón A, Fernández JR; Hygia Project Investigators. Comparing the design of the primary-care based Hygia Chronotherapy Trial and the Internet-Based TIME Study. *Eur Heart J*. 2020;41:1608. doi: 10.1093/eurheartj/ehaa276
 91. Hermida RC, Fernández JR, Mojón A; Hygia Project Investigators. Chronotherapy of hypertension, asleep ambulatory blood pressure, and glaucoma. *Eur Heart J*. 2020;41:1605. doi: 10.1093/eurheartj/ehaa215
 92. Hermida RC, Crespo JJ, Domínguez-Sardiña M. Improved reduction of cardiovascular risk by bedtime ingestion of ARB and ACEI medication class therapies. *Eur Heart J*. 2020;41:1602–1603. doi: 10.1093/eurheartj/ehaa214
 93. Poulter NR, Savopoulos C, Anjum A, Apostolopoulou M, Chapman N, Cross M, Falaschetti E, Fotiadis S, James RM, Kanellos I, et al. Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure. *Hypertension*. 2018;72:870–873. doi: 10.1161/HYPERTENSIONAHA.118.11101
 94. Rorie DA, Rogers A, Mackenzie IS, Ford I, Webb DJ, Williams B, Brown M, Poulter N, Findlay E, Saywood W, et al. Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. *BMJ Open*. 2016;6:e010313. doi: 10.1136/bmjopen-2015-010313
 95. Asmar R, Gosse P, Queré S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. *Blood Press Monit*. 2011;16:80–86. doi: 10.1097/MBP.0b013e318238344c6db
 96. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbaï F, Hiremath L, Jamerson K, et al. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. *Hypertension*. 2013;61:82–88. doi: 10.1161/HYPERTENSIONAHA.112.200477
 97. Rorie DA, Flynn RW, Mackenzie IS, MacDonald TM, Rogers A. The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment. *Trials*. 2017;18:557. doi: 10.1186/s13063-017-2318-4
 98. De Giorgi A, Mallozzi Menegatti A, Fabbian F, Portaluppi F, Manfredini R. Circadian rhythms and medical diseases: does it matter when drugs are taken? *Eur J Intern Med*. 2013;24:698–706. doi: 10.1016/j.ijim.2013.03.019
 99. Dong D, Yang D, Lin L, Wang S, Wu B. Circadian rhythm in pharmacokinetics and its relevance to chronotherapy. *Biochem Pharmacol*. 2020;178:114045. doi: 10.1016/j.bcp.2020.114045
 100. Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure. *Adv Drug Deliv Rev*. 2007;59:923–939. doi: 10.1016/j.addr.2006.09.021
 101. Khodadoust S, Nasri Ashrafi I, Vanaja Satheesh K, Kumar C, Hs S, S C. Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. *Clin Exp Hypertens*. 2017;39:520–526. doi: 10.1080/10641963.2017.1281947
 102. Ueno K, Sato H. Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs. *Hypertens Res*. 2012;35:245–250. doi: 10.1038/hr.2011.189
 103. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, Ceconi C, Drexel H, Kjeldsen K, Savarese G, et al. Gender differences in the effects of cardiovascular drugs. *Eur Heart J Cardiovasc Pharmacother*. 2017;3:163–182. doi: 10.1093/ehjcvp/pww042

104. Kalibala J, Pechère-Bertschi A, Desmeules J. Gender differences in cardiovascular pharmacotherapy—the example of hypertension: a mini review. *Front Pharmacol*. 2020;11:564. doi: 10.3389/fphar.2020.00564
105. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. *Clin Pharmacol Ther*. 1999;66:594–601. doi: 10.1053/cp.1999.v66.103400001
106. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. *Clin Pharmacol Ther*. 1989;46:257–263. doi: 10.1038/clpt.1989.136
107. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. *J Hypertens*. 2002;20:2183–2189. doi: 10.1097/00004872-200211000-00017
108. Puttonen S, Härmä M, Hublin C. Shift work and cardiovascular disease - pathways from circadian stress to morbidity. *Scand J Work Environ Health*. 2010;36:96–108. doi: 10.5271/sjweh.2894
109. Manohar S, Thongprayoon C, Cheungpasitporn W, Mao MA, Herrmann SM. Associations of rotational shift work and night shift status with hypertension: a systematic review and meta-analysis. *J Hypertens*. 2017;35:1929–1937. doi: 10.1097/HJH.0000000000001442
110. Ferguson JM, Costello S, Neophytou AM, Balmes JR, Bradshaw PT, Cullen MR, Eisen EA. Night and rotational work exposure within the last 12 months and risk of incident hypertension. *Scand J Work Environ Health*. 2019;45:256–266. doi: 10.5271/sjweh.3788
111. Uhm JY, Kim HR, Kang GH, Choi YG, Park TH, Kim SY, Chang SS, Choo WO. The association between shift work and chronic kidney disease in manual labor workers using data from the Korea National Health and Nutrition Examination Survey (KNHANES 2011–2014). *Ann Occup Environ Med*. 2018;30:1–12. doi: 10.1186/s40557-018-0279-z eCollection 2018
112. Hill AM, Crislip GR, Stowie A, Ellis I, Ramsey A, Castanon-Cervantes O, Gumz ML, Davidson AJ. Environmental circadian disruption suppresses rhythms in kidney function and accelerates excretion of renal injury markers in urine of male hypertensive rats. *Am J Physiol Renal Physiol*. 2021;320:F224–F233. doi: 10.1152/ajprenal.00421.2020
113. Patterson PD, Mountz KA, Budd CT, Bubbs JL, Hsin AU, Weaver MD, Turner RL, Platt TE, Guyette FX, Martin-Gill C, et al. Impact of shift work on blood pressure among emergency medical services clinicians and related shift workers: a systematic review and meta-analysis. *Sleep Health*. 2020;6:387–398. doi: 10.1016/j.sleh.2020.03.006